Home

mähen Ihre akademisch nmd pharma aarhus heilig Scheune Zuhause

NMD Pharma - Capnova
NMD Pharma - Capnova

Nmd Pharma A/S, Aarhus N | firma | krak.dk
Nmd Pharma A/S, Aarhus N | firma | krak.dk

Company Presentation
Company Presentation

NMD Pharma to advance neuromuscular disorder therapies with €38m Series A  round
NMD Pharma to advance neuromuscular disorder therapies with €38m Series A round

NMD Pharma
NMD Pharma

NMD Pharma — NMD Pharma
NMD Pharma — NMD Pharma

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

NMD Pharma
NMD Pharma

NMD Pharma
NMD Pharma

NMD Pharma ApS Annual Report for 1 January - 31 December 2017
NMD Pharma ApS Annual Report for 1 January - 31 December 2017

NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance  Treatments of Neuromuscular Disorders
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders

Big deal: NMD flexes series A muscles - Global University Venturing
Big deal: NMD flexes series A muscles - Global University Venturing

Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus
Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

Management — NMD Pharma
Management — NMD Pharma

NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering

Nmd Pharma A/S, Aarhus N | firma | krak.dk
Nmd Pharma A/S, Aarhus N | firma | krak.dk

NMD Pharma
NMD Pharma

NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial  of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

Event: Aarhus - Brew Your Own: Meet the founders - Biopeople
Event: Aarhus - Brew Your Own: Meet the founders - Biopeople

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for  the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis